Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results
Date:3/10/2011

antibiotic therapy delivered via proprietary advanced pulmonary liposome technology in areas of high unmet need in lung diseases.  For more information, please visit http://www.insmed.com.

Forward-Looking Statements This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to our financial position, results of operations, the development of our products, and business strategies, plans and objectives of management, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements.  Our results may also be affected by such factors as the receipt and timing of FDA and other regulatory approvals, if at all, competitive developments affecting our product development, delays in product development or clinical trials, and patent disputes involving currently developing products.  The risks and uncertainties include, without limitation, we may be unsuccessful in developing our product candidates or receiving necessary regulatory approvals, our product candidates may not prove to be commercially successful, our expenses may be higher than anticipated and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2009.  Investors are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release.  We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated e
'/>"/>

SOURCE Insmed Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Insmed to Host Second Quarter 2009 Conference Call
2. Insmed Announces Addition to the Russell 3000(R) Index
3. Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
4. Insmed CEO Resigns Due to Health Concerns
5. Insmed Announces First Quarter 2009 Financial Results
6. Insmed Regains NASDAQ Compliance
7. Insmed to Host First Quarter 2009 Conference Call
8. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
9. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
10. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
11. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... (PRWEB) March 26, 2015 PRC Clinical, ... announced today several management and executive appointments effective immediately. ... Financial Officer (CFO) and member of the Board of ... Business Operations, and Sue Dowden will assume the position ... and current Chief Operations Officer (COO), has been appointed ...
(Date:3/26/2015)... The Market Element LLC, a leading inbound marketing ... Gig LLC to provide website design, development, and creative ... alliance with Designing Gig represents a pivotal moment for ... end-to-end, digital solution for our clients, which now includes ... president of The Market Element. “For small and mid-sized ...
(Date:3/26/2015)... Massachusetts and CINCINNATI ... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... a three-year, broad research collaboration for rare diseases. The ... develop novel therapies to treat rare diseases with ... commercialization capabilities with Cincinnati Children,s research expertise. As ...
(Date:3/26/2015)... March 26, 2015 PAREXEL International ... clinical research organization , announced today ... agreement to acquire all of the business ... leading provider of specialized pharmacovigilance services, based ... collection, detection, assessment, monitoring, and prevention of ...
Breaking Biology Technology:PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today ... Phase 2 clinical trial using intravenous,administration of REOLYSIN(R) ... advanced head and neck cancers. The Principal,Investigator is ... Research Center,(CTRC) at The University of Texas Health ...
... Inc. (Amex:,SGN) announced that it has filed its Form ... of trading of its common stock,on the American Stock ... trade on AMEX will be Friday, September 12, 2008.,Signalife ... for,quotation on both the Over-The-Counter Bulletin Board and the ...
... 8 On Wednesday, October,22, 2008, Wyeth (NYSE: ... quarter. The Company will hold a one-hour conference call ... 22, 2008. Interested,investors and others may listen to the ... webcast, which may be accessed by visiting our website,at ...
Cached Biology Technology:Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 3Signalife Announces Anticipated Date of Transition to OTCBB 2
(Date:3/10/2015)... , March 10, 2015  Continuing its 167-year ... Unexpected, Hammacher Schlemmer introduces The Eye Scanning Password ... before granting access to secure websites or sensitive data. ... verify travelers at international borders, the device has a ... pattern points of the iris, converting them into an ...
(Date:3/10/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce ... been named the "Number One Best Tech Gift ... Modern ( http://www.rethinkmodern.com/ ) is a web magazine focused ... that have a unique function or design.  ...
(Date:3/3/2015)... , March 3, 2015 ... provider of advanced cryogenic logistics solutions for ... immunotherapies, stem cells, cell lines, clinical research ... medicine, today announced the expansion of its ... Centers, ("Fred Hutch") Clinical Research Division ...
Breaking Biology News(10 mins):Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... 18th century natural philosopher Jean-Baptiste Lamarck proposed that the ... cumulative effort, across generations, to reach leaves just out ... abandoned with the advent of modern genetic theories to ... medical illnesses across generations. However, there has long ...
... February 13, 2013, Cleveland: Cleveland Clinic researchers have found ... genetic screening for Lynch syndrome, the most common hereditary, ... online version of the Journal of Clinical Oncology ... cause of colon cancer in adults. The study found ...
... can affect the knowledge and behaviour of their parents, ... London surveyed the families of 160 schoolchildren in the ... about the island,s valuable wetland resources. They found ... the wetland activities were more knowledgeable about wetlands and, ...
Cached Biology News:Life experiences put their stamp on the next generation: New insights from epigenetics 2Cleveland Clinic develops clinical screening program for no.1 genetic cause of colon cancer 2Cleveland Clinic develops clinical screening program for no.1 genetic cause of colon cancer 3Environment schemes for kids influence parents' behavior 2
Goat polyclonal to T7 tag (Agarose) Immunogen: Goats were immunized with MASMTGGQQMG (T7) conjugated to KLH.After multiple immunizations in Freund's adjuvant, serum was collected....
... The features we add to WinList ... the product every day. Features like automatic ... are the result of good suggestions, thoughtful ... of the features you depend on are ...
C/EBPdelta Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Rabbit polyclonal to Orexin Prepro ( Abpromise for all tested applications). entrezGeneID: 3060 SwissProtID: O43612...
Biology Products: